Department of Occupational Health and Environmental Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610041, China.
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Biometals. 2021 Jun;34(3):557-571. doi: 10.1007/s10534-021-00295-z. Epub 2021 Mar 10.
Sodium metavanadate (NaVO) exhibits important physiological effects including insulin-like, chemoprevention and anticancer activity. However, the effects of NaVO on breast cancer and underlying mechanisms are still unclear. In this study, our results revealed that NaVO was able to inhibit proliferation of murine breast cancer cells 4T1 with IC value of 8.19 μM and 1.92 μM at 24 h and 48 h, respectively. The mechanisms underlying the inhibition activity were that NaVO could increase reactive oxygen species (ROS) level in a concentration-dependent way, arrest cells at G2/M phase, diminish the mitochondrial membrane potential (MMP), finally promote the progress of apoptosis. Furthermore, NaVO also exhibited a dose-dependent anticancer activity in breast cancer-bearing mice that led to the shrinkage of tumor volume (about 50%), lower microvessel density, less propagating cells and more apoptotic cells in vivo, as compared to the saline group. Therefore, NaVO may act as a potential chemotherapeutic agent in breast cancer treatment.
偏钒酸钠（NaVO）具有胰岛素样、化学预防和抗癌活性等重要的生理作用。然而，NaVO 对乳腺癌的作用及其机制尚不清楚。在这项研究中，我们的结果表明，NaVO 能够抑制小鼠乳腺癌细胞 4T1 的增殖，在 24 小时和 48 小时时，IC 值分别为 8.19 μM 和 1.92 μM。抑制活性的机制是 NaVO 能够以浓度依赖的方式增加活性氧（ROS）水平，将细胞阻滞在 G2/M 期，降低线粒体膜电位（MMP），最终促进细胞凋亡。此外，NaVO 在荷瘤小鼠中也表现出剂量依赖性的抗癌活性，导致肿瘤体积缩小（约 50%），微血管密度降低，增殖细胞减少，凋亡细胞增多，与生理盐水组相比。因此，NaVO 可能是一种治疗乳腺癌的潜在化疗药物。
